stockrow
Friday 6 November 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
63.83
1.91
+3.08%
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Gross margin
Vaxcyte, Inc.'s gross margin over the twelve months to 30 September 2023 was 0.00%, down 0.0 percentage points from fiscal 2022 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2022) to 0.00% (fiscal 2022) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2023 | 0.00% | 0.00 |
| Jun 2023 | 0.00% | 0.00 |
| Mar 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| 12 more quarters | Free account |
Against its own ten years
Low 0.00%
High 0.00%
Ten-year median
0.00%
Current reading's percentile
100
Gross margin against peers
| Company | Gross margin |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 100.0% |
| IBRX ImmunityBio, Inc. compare | 99.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 91.0% |
| TGTX TG Therapeutics, Inc. compare | 82.4% |
| BMRN BioMarin Pharmaceutical Inc. compare | 76.0% |
| TECH Bio-Techne Corp compare | 65.8% |
| TWST Twist Bioscience Corporation compare | 52.0% |
| PCVX Vaxcyte, Inc. | 0.00% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue